With lat­est 18-month da­ta cut, Take­da push­es to­ward 2021 launch of dengue vac­cine — can they side­step Sanofi's dis­as­ter?

Take­da’s dengue vac­cine has passed the sec­ond of a three-part late-stage test, the com­pa­ny says, buff­ing up a da­ta pack­age that they ex­pect to take to reg­u­la­tors late next year — but rais­ing con­cerns around a par­tic­u­lar sub­group and falling ef­fi­ca­cy rates.

At 18 months af­ter the sec­ond dose, in­ves­ti­ga­tors are track­ing an over­all ef­fi­ca­cy rate of 73% — down from the 80.2% re­port­ed at the 12-month time point. But equal­ly sig­nif­i­cant are the sec­ondary end­points mea­sur­ing clin­i­cal im­pli­ca­tions, said Derek Wal­lace, the glob­al dengue lead.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER